ReviewFuture oncology (London, England)2017
Targeting acute myeloid leukemia with TP53-independent vosaroxin.
Christopher B Benton et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this papertrialcites it
ReviewFuture oncology (London, England)2017
Christopher B Benton et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.